Covered recipient · General Payments record
MICHELLE ANGELA NORRIS
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
General Payments · PY2021–2024
$3,632.20
- Reported across 91 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,117.94 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $243.20 | 2 |
| Acerta Pharma LLC | $236.35 | 2 |
| Vanda Pharmaceuticals Inc. | $196.98 | 2 |
| Alkermes, Inc. | $120.00 | 1 |
| ABBVIE INC. | $119.88 | 1 |
| Tris Pharma Inc | $108.85 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $92.68 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $119.88 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105133235 | CMS |
| Alkermes, Inc. | $120.00 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120563982 | CMS |
| AstraZeneca Pharmaceuticals LP | $114.52 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1123309958 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.83 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1123309448 | CMS |
| Axsome Therapeutics, Inc. | $121.60 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148306364 | CMS |
| Axsome Therapeutics, Inc. | $121.60 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148394491 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $92.68 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146784940 | CMS |
| Tris Pharma Inc | $108.85 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147232645 | CMS |
| Vanda Pharmaceuticals Inc. | $81.78 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133961309 | CMS |
| Vanda Pharmaceuticals Inc. | $115.20 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133961311 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.